Title: A Multicenter, Double-blind, Randomized, Placebo Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of SPM 927 (400 and 600mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization.
Principal Investigator: Maria Sam, M.D.
Multi-site, randomized double-blind, add-on therapy on SPM927 or placebo, for refractory partial epilepsy.
Inclusion Criteria: Refractory partial onset epilepsy patients/age 16 to 70/treating with 1 to 3 AEDs/averaging atleast 4 seizures per 28 days.
Epilepsy (Completed)
Contact: Nancy Buchheimer
336-716-3961
nbuchhe@wfubmc.edu
Sponsor: Swartz (Completed)